New Triple-Threat treatment tested before oral cancer surgery
NCT ID NCT07335380
Summary
This early-stage study aims to find the safest dose of a new pre-surgery treatment for oral cavity cancer. The treatment combines a special form of targeted radiation with chemotherapy and immunotherapy. About 30 patients with advanced but operable oral cancer will receive this combination 6-8 weeks before their standard surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.